National plaintiffs' law firm Berger Montague PCis investigating securities fraud claims againstSpectrum Pharmaceuticals, Inc. (NASDAQ: SPPI) (“Spectrum” or the “Company”) on behalf of investors who purchased or otherwise acquired common shares of Spectrum betweenMarch 17, 2022 through September 22, 2022 (the “Class Period”).
https://mma.prnewswire.com/media/232479/berger_montague.jpg
Investor Deadline:Investors who purchased or acquired Spectrum securities during the Class Period may, no later than September 24, 2025, seek to be appointed as a lead plaintiff representative of the class. To learn your rights,CLICK HERE.
Spectrum is a biopharmaceutical company focused on oncology treatments.
The class action lawsuit alleges that Spectrum made false or misleading statements to investors regarding its Pinnacle Study, a clinical trial involving poziotinib, a drug intended to treat certain lung cancer patients.
Spectrum shares were delisted following the Company's merger with Assertio Holdings, Inc. (NASDAQ: ASRT).
If you are a Spectrum investor and would like to learn more about this action, CLICK HEREor please contact Berger Montague: Andrew Abramowitz at aabramowitz@bergermontague.com or (215) 875-3015, or Caitlin Adorni at cadorni@bergermontague.com or (267)764-4865.
About Berger MontagueBerger Montague, with offices in Philadelphia, Minneapolis, Delaware, Washington, D.C., San Diego, San Francisco, Chicago, Malvern, PA, and Toronto has been a pioneer in securities class action litigationsince its founding in 1970. Berger Montague has represented individual and institutional investors for over five decades and serves as lead counsel in courts throughout the United States.
For more information or to discuss your rights, please contact:Andrew Abramowitz, Senior CounselBerger Montague(215) 875-3015aabramowitz@bergermontague.com
Caitlin AdorniBerger Montague(267) 764-4865cadorni@bergermontague.com
https://c212.net/c/img/favicon.png?sn=DC45853&sd=2025-08-06
View original content to download multimedia:https://www.prnewswire.com/news-releases/berger-montague-pc-investigating-claims-on-behalf-of-spectrum-pharmaceuticals-inc-nasdaq-sppi-investors-302523466.html
SOURCE Berger Montague
https://rt.newswire.ca/rt.gif?NewsItemId=DC45853&Transmission_Id=202508061541PR_NEWS_USPR_____DC45853&DateId=20250806